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Objective: To report the utilization of spironolactone, rate of hyperkalemia, readmission and all-cause mortality in select group of patients with 
congestive heart failure (CHF).
Methods: This was a retrospective chart review of consecutive patients hospitalized at Unity Hospital with discharge diagnosis of CHF from 
December 2007 to December 2008. Patients with symptomatic heart failure with (LVEF) of < 35%, serum creatinine <2.5 mg/dL and serum K less 
than 5mEq/L were included. Information was collected regarding LVEF, co-morbid conditions, renal function, serum potassium, and readmission for 
CHF at 30 days. All-cause mortality was determined from the National Death Registry.
Results: There were 390 patients admitted with discharge diagnosis of CHF. Spironolactone was used in 57 (15%) patients. There were 134 
patients who had LVEF of < 35%, serum creatinine <2.5 mg/dL and serum K less than 5mEq/L. Spironolactone was prescribed in only 34 (25%) 
patients. Patients who were on spirinolactone were younger (p 0.03). Although serum potassium was higher in patients on spironolactone (p 0.009) 
there were no reports of hyperkalemia. There was no difference in readmission at 30 days and total mortality (p 0.85, 0.85) respectively. Comparison 
of the patients by spironolactone use is shown in the table.
Conclusion: Spironolactone is underutilized in heart failure patients. Our study did not find increase rate of hyperkalemia, with no difference in 
30-day readmission or total mortality with spironolactone use. 
Spironolactone (Yes)
N=34
Spironolactone(No)
N=100
P value
Age (years) 75.1+ 10.3 79.4+ 9.7 0.03
Gender (F) 20(58.8) 47(47) 0.23
Hypertension 25(73.5) 76(76) 0.77
Coronary artery disease 24(70.6) 65(65) 0.55
Diabetes Mellitus 20(58.8) 45(45) 0.16
Potassium (mEq/L) 4.02+ 0.36 4.2 + 0.37 0.009
Creatinine (mg/dl) 1.33+ 0.38 1.28+ 0.42 0.56
Beta blocker 32(94.1) 89(89) 0.08
ACEI/ARB 23 (67.6) 72 (72) 0.22
All-cause mortality 21(61.8) 60 (60) 0.85
Readmission at 30 days 7 (20.1) 17 (17) 0.85
